EICHOR
● Active Not Recruiting
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
Condition: Astrocytoma, IDH-Mutant, Grade 2 · Astrocytoma, IDH-Mutant, Grade 3 · Sponsor: National Cancer Institute (NCI)
About this study
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. Telaglenastat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving telaglenastat with radiation therapy and temozolomide may work better than surgery, radiation therapy, and temozolomide in treating patients with IDH-mutated diffuse astrocytoma or anaplastic astrocytoma.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (25)
| Mayo Clinic Hospital in Arizona | Phoenix, Arizona, United States | — |
| Mayo Clinic in Arizona | Scottsdale, Arizona, United States | — |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange, California, United States | — |
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | — |
| Mayo Clinic in Florida | Jacksonville, Florida, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City, Iowa, United States | — |
| University of Kentucky/Markey Cancer Center | Lexington, Kentucky, United States | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore, Maryland, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| University of Michigan Rogel Cancer Center | Ann Arbor, Michigan, United States | — |
+ 13 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.